Kidney Medicine最新文献

筛选
英文 中文
Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases 原发性高草酸尿症 1 型患者妊娠期尿草酸盐排泄情况:4 例报告
IF 3.9
Kidney Medicine Pub Date : 2024-04-16 DOI: 10.1016/j.xkme.2024.100824
Jing Miao , Ramila A. Mehta , Andrea Kattah , Suzanne M. Norby , John C. Lieske , Dawn S. Milliner
{"title":"Urinary Oxalate Excretion During Pregnancy in Primary Hyperoxaluria Type 1: A Report of 4 Cases","authors":"Jing Miao ,&nbsp;Ramila A. Mehta ,&nbsp;Andrea Kattah ,&nbsp;Suzanne M. Norby ,&nbsp;John C. Lieske ,&nbsp;Dawn S. Milliner","doi":"10.1016/j.xkme.2024.100824","DOIUrl":"10.1016/j.xkme.2024.100824","url":null,"abstract":"<div><p>Primary hyperoxaluria (PH) is a rare genetic disorder characterized by excessive oxalate production because of specific gene defects. PH1 is the most prevalent type, causing recurrent kidney stone disease and often leading to chronic kidney disease and kidney failure. Our previous study suggested that pregnancy did not adversely affect kidney function in female patients with PH. In this study, we identified 4 PH1 cases with urinary oxalate (UOx) measurements during pregnancy from the Rare Kidney Stone Consortium and Oxalosis and Hyperoxaluria Foundation PH registry to investigate UOx levels during pregnancy in patients with PH1. The PH Registry is approved by the Institutional Review Board of Mayo Clinic (Rochester, MN). All 4 showed a decrease in UOx during pregnancy when compared with before pregnancy and after delivery. These findings contrast with those of the general population, in which the UOx tends to increase during pregnancy because of a simultaneous physiological increase in the glomerular filtration rate. Elucidating the mechanism underlying reduced UOx during pregnancy in PH1 could suggest novel PH therapies. These findings could also affect the clinical management and have implications regarding the safety of withholding novel PH1-directed molecular therapies that currently have uncertain safety profiles during pregnancy. We highlight the need for additional data on urinary changes in patients with PH and other populations while pregnant to clarify changes in UOx throughout pregnancy.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000359/pdfft?md5=73a5ee830a46c3856615d37d3421b04a&pid=1-s2.0-S2590059524000359-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140796584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Kidney Injury and Subsequent Kidney Failure With Replacement Therapy Incidence in Older Adults With Advanced CKD: A Cohort Study of US Veterans 美国退伍军人队列研究:晚期慢性肾脏病老年人的 AKI 和后续肾衰竭替代疗法发生率
IF 3.9
Kidney Medicine Pub Date : 2024-04-16 DOI: 10.1016/j.xkme.2024.100825
Danira Medunjanin , Bethany J. Wolf , Roberto Pisoni , David J. Taber , John L. Pearce , Kelly J. Hunt
{"title":"Acute Kidney Injury and Subsequent Kidney Failure With Replacement Therapy Incidence in Older Adults With Advanced CKD: A Cohort Study of US Veterans","authors":"Danira Medunjanin ,&nbsp;Bethany J. Wolf ,&nbsp;Roberto Pisoni ,&nbsp;David J. Taber ,&nbsp;John L. Pearce ,&nbsp;Kelly J. Hunt","doi":"10.1016/j.xkme.2024.100825","DOIUrl":"10.1016/j.xkme.2024.100825","url":null,"abstract":"<div><h3>Rationale &amp; Objective</h3><p>Advanced age is a major risk factor for chronic kidney disease (CKD) development, which has high heterogeneity in disease progression. Acute kidney injury (AKI) hospitalization rates are increasing, especially among older adults. Previous AKI epidemiologic analyses have focused on hospitalized populations, which may bias results toward sicker populations. This study examined the association between AKI and incident kidney failure with replacement therapy (KFRT) while evaluating age as an effect modifier of this relationship.</p></div><div><h3>Study Design</h3><p>Retrospective cohort study.</p></div><div><h3>Setting &amp; Participants</h3><p>24,133 Veterans at least 65 years old with incident CKD stage 4 from 2011 to 2013.</p></div><div><h3>Exposures</h3><p>AKI, AKI severity, and age.</p></div><div><h3>Outcomes</h3><p>KFRT and death.</p></div><div><h3>Analytical Approach</h3><p>The Fine-Gray competing risk regression was used to model AKI and incident KFRT with death as a competing risk. A Cox regression was used to model AKI severity and death.</p></div><div><h3>Results</h3><p>Despite a nonsignificant age interaction between AKI and KFRT, a clinically relevant combined effect of AKI and age on incident KFRT was observed. Compared with our oldest age group without AKI, those aged 65-74 years with AKI had the highest risk of KFRT (subdistribution HR [sHR], 14.9; 95% CI, 12.7-17.4), whereas those at least 85 years old with AKI had the lowest (sHR, 1.71; 95% CI, 1.22-2.39). Once Veterans underwent KFRT, their risk of death increased by 44%. A 2-fold increased risk of KFRT was observed across all AKI severity stages. However, the risk of death increased with worsening AKI severity.</p></div><div><h3>Limitations</h3><p>Our study lacked generalizability, was restricted to ever use of medications, and used inpatient serum creatinine laboratory results to define AKI and AKI severity.</p></div><div><h3>Conclusions</h3><p>In this national cohort, advanced age was protective against incident KFRT but not death. This is likely explained by the high frequency of deaths observed in this population (51.1%). Nonetheless, AKI and younger age are substantial risk factors for incident KFRT.</p></div><div><h3>Plain Language Summary</h3><p>Older adults are at risk of acute kidney injury (AKI) and subsequent nonrecovery from AKI, resulting in long-term dialysis. Hospitalized patients have often been used in the past to study AKI. This could lead to biased conclusions when inferring from sicker populations. That is why we created a national cohort of 24,133 Veterans at least 65 years old with incident chronic kidney disease (CKD) stage 4 to examine the relationship between AKI and age and subsequent kidney failure with replacement therapy (KFRT). The data have showed that AKI and younger age are substantial risk factors for incident KFRT. As for older age, it appears to be protective against KFRT but not death. This is likely ex","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000360/pdfft?md5=053368f03f34f71c9c2f30ed6622d81a&pid=1-s2.0-S2590059524000360-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases 肾移植后复发性 C3 肾小球病中的 B 因子抑制与 Iptacopan:两个病例的报告
IF 3.9
Kidney Medicine Pub Date : 2024-04-12 DOI: 10.1016/j.xkme.2024.100823
Víctor J. Escudero-Saiz , Ángela Gonzalez , Adriana García-Herrera , Ana B. Larque , Andrew S. Bomback , Laura Morantes , Marta Martínez-Chillarón , Júlia Ollé , Elena Guillén , Marc Xipell , Alicia Molina-Andújar , Diana Rodríguez , Elena Cuadrado , Judit Cacho , Carolt Arana , Núria Esforzado , Carla Bastida , Esteban Poch , Fritz Diekman , David Cucchiari , Miquel Blasco
{"title":"Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases","authors":"Víctor J. Escudero-Saiz ,&nbsp;Ángela Gonzalez ,&nbsp;Adriana García-Herrera ,&nbsp;Ana B. Larque ,&nbsp;Andrew S. Bomback ,&nbsp;Laura Morantes ,&nbsp;Marta Martínez-Chillarón ,&nbsp;Júlia Ollé ,&nbsp;Elena Guillén ,&nbsp;Marc Xipell ,&nbsp;Alicia Molina-Andújar ,&nbsp;Diana Rodríguez ,&nbsp;Elena Cuadrado ,&nbsp;Judit Cacho ,&nbsp;Carolt Arana ,&nbsp;Núria Esforzado ,&nbsp;Carla Bastida ,&nbsp;Esteban Poch ,&nbsp;Fritz Diekman ,&nbsp;David Cucchiari ,&nbsp;Miquel Blasco","doi":"10.1016/j.xkme.2024.100823","DOIUrl":"10.1016/j.xkme.2024.100823","url":null,"abstract":"<div><p>C3 glomerulopathy is a rare disease caused by fluid phase dysregulation of the alternative complement pathway. Currently, treatment depends on clinical and histological severity and includes nephroprotection, unspecific immunosuppression, and terminal complement blockers (C5), without having an etiological treatment approved. C3 glomerulopathy has high recurrence rates after kidney transplantation with a high risk of graft loss. Fortunately, new molecules are being developed that specifically target the proximal alternative complement pathway, such as iptacopan, a factor B inhibitor that showed promising results in native kidneys and cases of transplant recurrence in a phase 2 clinical trial. We present 2 “real-world” cases of C3 glomerulopathy recurrence in kidney allografts treated with iptacopan, with initial excellent clinical response and safety profile, especially with early introduction. We also present follow-up biopsies that showed no C3 deposition during factor B inhibition. Our cases suggest that proximal blockade of the alternative complement pathway can be effective and safe in the treatment of C3 glomerulopathy recurrence in kidney transplantation, bringing other questions such as dual blockade (eg, in C3 and C5), the optimal patient profile to benefit from factor B inhibition or treatment duration and its potential use in other forms of membranoproliferative glomerulonephritis (eg, immune complex-mediated).</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000347/pdfft?md5=b44683c9a22345d8860e8aacf690c347&pid=1-s2.0-S2590059524000347-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pretransplant Treatment to Avoid Recurrent Membranous Nephropathy in a Kidney Transplant Recipient: A Case Report 避免肾移植受者复发膜性肾病的移植前治疗:病例报告
IF 3.9
Kidney Medicine Pub Date : 2024-04-12 DOI: 10.1016/j.xkme.2024.100822
Erik L. Lum , Jonathan E. Zuckerman , Lama Abdelnour , Jennifer Terenzini , Gurbir Singh , Suphamai Bunnapradist
{"title":"Pretransplant Treatment to Avoid Recurrent Membranous Nephropathy in a Kidney Transplant Recipient: A Case Report","authors":"Erik L. Lum ,&nbsp;Jonathan E. Zuckerman ,&nbsp;Lama Abdelnour ,&nbsp;Jennifer Terenzini ,&nbsp;Gurbir Singh ,&nbsp;Suphamai Bunnapradist","doi":"10.1016/j.xkme.2024.100822","DOIUrl":"10.1016/j.xkme.2024.100822","url":null,"abstract":"<div><p>Kidney transplant candidates with high anti–M-type phospholipase A2 receptor antibody activity may be at increased risk for early postkidney transplant recurrence and allograft loss. Pretransplant treatment to induce serological remission may be warranted to improve allograft survival. In this case report, a patient seeking their third kidney transplant, who lost 2 prior living donor transplants from early recurrent membranous nephropathy, underwent pretransplant treatment for membranous nephropathy with serological remission and no evidence of recurrent disease.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000335/pdfft?md5=d3c1b89f91dbce73ccd3cf483f24a0e1&pid=1-s2.0-S2590059524000335-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
23NaMRI Assessed Cyst Sodium Concentration in Polycystic Kidney Disease to Identify Cyst Metabolic Activity: A Proof of Concept Study 23NaMRI 评估多囊肾患者的囊钠浓度以确定囊代谢活动:概念验证研究
IF 3.9
Kidney Medicine Pub Date : 2024-04-11 DOI: 10.1016/j.xkme.2024.100820
Sandrine Lemoine MD, PhD , Alireza Akbari PhD , Christopher W. McIntyre MD, PhD
{"title":"23NaMRI Assessed Cyst Sodium Concentration in Polycystic Kidney Disease to Identify Cyst Metabolic Activity: A Proof of Concept Study","authors":"Sandrine Lemoine MD, PhD ,&nbsp;Alireza Akbari PhD ,&nbsp;Christopher W. McIntyre MD, PhD","doi":"10.1016/j.xkme.2024.100820","DOIUrl":"10.1016/j.xkme.2024.100820","url":null,"abstract":"","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000311/pdfft?md5=e17dc9ac5310362bbe139fda111ca146&pid=1-s2.0-S2590059524000311-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140767254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Importance of Recognizing Pain in Patients With Autosomal Dominant Polycystic Kidney Disease 认识常染色体显性遗传多囊肾患者疼痛的重要性
IF 3.9
Kidney Medicine Pub Date : 2024-04-09 DOI: 10.1016/j.xkme.2024.100821
Paul Geertsema , Ruud Stellema , Niek F. Casteleijn
{"title":"The Importance of Recognizing Pain in Patients With Autosomal Dominant Polycystic Kidney Disease","authors":"Paul Geertsema ,&nbsp;Ruud Stellema ,&nbsp;Niek F. Casteleijn","doi":"10.1016/j.xkme.2024.100821","DOIUrl":"https://doi.org/10.1016/j.xkme.2024.100821","url":null,"abstract":"","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000323/pdfft?md5=0652c7dea5f9ce7a0d088be96ceccd32&pid=1-s2.0-S2590059524000323-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140605915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deprescribing in Dialysis: Operationalizing “Less is More” Through a Multimodal Deprescribing Intervention 透析中的去处方:通过多模式去处方干预来实现 "少即是多"
IF 3.9
Kidney Medicine Pub Date : 2024-04-04 DOI: 10.1016/j.xkme.2024.100819
Madhusudan Vijayan , Dinushika Mohottige
{"title":"Deprescribing in Dialysis: Operationalizing “Less is More” Through a Multimodal Deprescribing Intervention","authors":"Madhusudan Vijayan ,&nbsp;Dinushika Mohottige","doi":"10.1016/j.xkme.2024.100819","DOIUrl":"https://doi.org/10.1016/j.xkme.2024.100819","url":null,"abstract":"","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259005952400030X/pdfft?md5=e2bab604ce60210e9d412dc1904df102&pid=1-s2.0-S259005952400030X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140640943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring Albuminuria in Individuals With Obesity: Pitfalls of the Urinary Albumin-Creatinine Ratio 测量肥胖症患者的白蛋白尿:尿白蛋白-肌酐比值的误区
IF 3.9
Kidney Medicine Pub Date : 2024-04-01 DOI: 10.1016/j.xkme.2024.100804
Avry Chagnac , Allon N. Friedman
{"title":"Measuring Albuminuria in Individuals With Obesity: Pitfalls of the Urinary Albumin-Creatinine Ratio","authors":"Avry Chagnac ,&nbsp;Allon N. Friedman","doi":"10.1016/j.xkme.2024.100804","DOIUrl":"https://doi.org/10.1016/j.xkme.2024.100804","url":null,"abstract":"<div><p>An increased urinary albumin excretion rate is an important early risk factor for chronic kidney disease and other major outcomes and is usually measured using the urinary albumin-creatinine ratio (ACR). Obesity is highly prevalent in the general and chronic kidney disease populations and is an independent risk factor for moderately increased albuminuria (henceforth, moderate albuminuria). In this review, we describe how the ACR was developed and used to define moderate albuminuria. We then investigate how biases related to urinary creatinine excretion are introduced into the ACR measurement and how the use of the 30-mg/g threshold decreases the performance of the test in populations with higher muscle mass, with a primary focus on why and how this occurs in the obese population. The discussion then raises several strategies that can be used to mitigate such bias. This review provides a comprehensive overview of the medical literature on the uses and limitations of ACR in individuals with obesity and critically assesses related issues. It also raises into question the widely accepted 30-mg/g threshold as universally adequate for the diagnosis of moderate albuminuria. The implications of our review are relevant for clinicians, epidemiologists, and clinical trialists.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000153/pdfft?md5=14d758b1eb4a07ee87875ebf6b6ede72&pid=1-s2.0-S2590059524000153-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140341524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
External Validation of the Kidney Failure Risk Equation Among Urban Community-Based Chinese Patients With CKD 中国城市社区慢性肾病患者肾衰竭风险方程的外部验证
IF 3.9
Kidney Medicine Pub Date : 2024-03-26 DOI: 10.1016/j.xkme.2024.100817
Ling Pan , Jinwei Wang , Yang Deng , Yexiang Sun , Zhenyu Nie , Xiaoyu Sun , Chao Yang , Guohui Ding , Ming-Hui Zhao , Yunhua Liao , Luxia Zhang
{"title":"External Validation of the Kidney Failure Risk Equation Among Urban Community-Based Chinese Patients With CKD","authors":"Ling Pan ,&nbsp;Jinwei Wang ,&nbsp;Yang Deng ,&nbsp;Yexiang Sun ,&nbsp;Zhenyu Nie ,&nbsp;Xiaoyu Sun ,&nbsp;Chao Yang ,&nbsp;Guohui Ding ,&nbsp;Ming-Hui Zhao ,&nbsp;Yunhua Liao ,&nbsp;Luxia Zhang","doi":"10.1016/j.xkme.2024.100817","DOIUrl":"10.1016/j.xkme.2024.100817","url":null,"abstract":"<div><h3>Rationale &amp; Objective</h3><p>The Kidney Failure Risk Equations have been proven to perform well in multinational databases, whereas validation in Asian populations is lacking. This study sought to externally validate the equations in a community-based chronic kidney disease cohort in China.</p></div><div><h3>Study Design</h3><p>A retrospective cohort study.</p></div><div><h3>Setting &amp; Participants</h3><p>Patients with and estimated glomerular filtration rate (eGFR) &lt; 60<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup> dwelling in an industrialized coastal city of China.</p></div><div><h3>Exposure</h3><p>Age, sex, eGFR, and albuminuria were included in the 4-variable model, whereas serum calcium, phosphate, bicarbonate, and albumin levels were added to the previously noted variables in the 8-variable model.</p></div><div><h3>Outcome</h3><p>Initiation of long-term dialysis treatment.</p></div><div><h3>Analytical Approach</h3><p>Model discrimination, calibration, and clinical utility were evaluated by Harrell’s C statistic, calibration plots, and decision curve analysis, respectively.</p></div><div><h3>Results</h3><p>A total of 4,587 participants were enrolled for validation of the 4-variable model, whereas 1,414 were enrolled for the 8-variable model. The median times of follow-up were 4.0 (interquartile range: 2.6-6.3) years for the 4-variable model and 3.4 (2.2-5.6) years for the 8-variable model. For the 4-variable model, the C statistics were 0.750 (95% CI: 0.615-0.885) for the 2-year model and 0.766 (0.625-0.907) for the 5-year model, whereas the values were 0.756 (0.629-0.883) and 0.774 (0.641-0.907), respectively, for the 8-variable model. Calibration was acceptable for both the 4-variable and 8-variable models. Decision curve analysis for the models at the 5-year scale performed better throughout different net benefit thresholds than the eGFR-based (&lt;30<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup>) strategy.</p></div><div><h3>Limitations</h3><p>A large proportion of patients lack albuminuria measurements, and only a subset of population could provide complete data for the 8-variable equation.</p></div><div><h3>Conclusions</h3><p>The kidney failure risk equations showed acceptable discrimination and calibration and better clinical utility than the eGFR-based strategy for incidence of kidney failure among community-based urban Chinese patients with chronic kidney disease.</p></div><div><h3>Plain-Language Summary</h3><p>Accurate and reliable risk evaluation of chronic kidney disease (CKD) prognosis can be helpful for physicians to make decisions concerning treatment opportunity and therapeutic strategy. The kidney failure risk equation is an outstanding model for predicting risk of kidney failure among patients with CKD. However, the equation is lacking validation among Chinese populations. In the current study, we demonstrated that the equation had good discrimination among an urban community-based cohort of patients with","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000281/pdfft?md5=e3746bf0072de8cf7641cb8f9de6a004&pid=1-s2.0-S2590059524000281-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140400262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney Replacement Therapy Use at End-of-Life Among Critically Ill Chinese and Non-Hispanic White Americans: A Single-Center Study 重症华裔和非西班牙裔美国白人临终前使用肾脏替代疗法的情况:一项单中心研究
IF 3.9
Kidney Medicine Pub Date : 2024-03-26 DOI: 10.1016/j.xkme.2024.100818
Seba Babroudi MD , Joshua Hyun Bin Whang BA , Avery C. Glover MD, MBA , Tamara Vesel MD , David A. Drew MD, MS
{"title":"Kidney Replacement Therapy Use at End-of-Life Among Critically Ill Chinese and Non-Hispanic White Americans: A Single-Center Study","authors":"Seba Babroudi MD ,&nbsp;Joshua Hyun Bin Whang BA ,&nbsp;Avery C. Glover MD, MBA ,&nbsp;Tamara Vesel MD ,&nbsp;David A. Drew MD, MS","doi":"10.1016/j.xkme.2024.100818","DOIUrl":"10.1016/j.xkme.2024.100818","url":null,"abstract":"","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000293/pdfft?md5=424bdbe950e9b5f204aa3a4fded2bb2b&pid=1-s2.0-S2590059524000293-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140400555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信